The Claim
Extending clinical follow-up after the final screening round in breast cancer trials substantially improves the precision of estimating the fraction of indolent tumors and the progression rate of progressive lesions, particularly when the mean sojourn time is short.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If doctors keep checking on women longer after their last breast cancer screening, they can better tell which tumors would never cause harm and which ones are likely to grow quickly—especially when cancers tend to develop slowly.
See the scientific wording
Extending clinical follow-up after the final screening round in breast cancer trials substantially improves the precision of estimating the fraction of indolent tumors and the progression rate of progressive lesions, particularly when the mean sojourn time is short.
What the research says
1 studyThis study found that keeping an eye on women longer after their last mammogram helps doctors better tell which breast cancers would never cause harm and which would grow, especially when cancers develop quickly. Without this extra follow-up, it's hard to know for sure.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.